Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
复制标题
DOI：
10.18632/oncotarget.10907
复制
发表时间：
2016-08-30
期刊：
影响因子：
--
通讯作者：
Jia Y
中科院分区：
文献类型：
--
作者：
Kong F;Gao F;Chen J;Sun Y;Zhang Y;Liu H;Li X;Yang P;Zheng R;Liu G;Jia Y
溶酶体相关蛋白跨膜4β-35（LAPTM 4 B-35）蛋白在非小细胞肺癌（NSCLC）中的表达水平及其临床意义尚不清楚。本研究旨在探讨LAPTM 4 B-35在NSCLC患者中的表达及预后价值。回顾性分析2007年至2011年107例接受根治性手术的NSCLC患者的临床病理和生存资料。检测LAPTM 4 B-35在配对肿瘤组织及癌旁正常组织中的表达，并分析其与临床变量的关系。进行Kaplan-Meier分析和考克斯回归（比例风险模型）来研究非小细胞肺癌的预后意义。LAPTM 4 B-35在NSCLC组织中过表达。LAPTM 4 B-35表达升高与癌症复发相关（P = 0.031）。LAPTM 4 B-35过表达组的5年中位OS和PFS显著更差。多因素考克斯分析显示LAPTM 4 B-35过表达是影响NSCLC患者OS和PFS的独立因素（分别为P = 0.018、P = 0.026）。LAPTM 4 B-35过表达是NSCLC独立的预后标志物，可预测肿瘤复发和不良生存期。有望成为NSCLC治疗的潜在靶点。
The expression levels and clinical significances of Lysosomal-associated protein transmembrane-4β-35 (LAPTM4B-35) protein are unknown in the non-small-cell lung cancer (NSCLC). This study aimed to explore the expression and prognostic value of LAPTM4B-35 in NSCLC patients. The clinicopathological and survival data of 107 NSCLC patients who received radical surgery from 2007 and 2011 were reviewed. The LAPTM4B-35 expression of the paired tumors and adjacent normal specimens were detected, and the association between LAPTM4B-35 and clinical variables was explored. Kaplan-Meier analysis and Cox regression (Proportional hazard model) were performed to investigate the prognostic significance for NSCLC. LAPTM4B-35 was over expressed in NSCLC tissues. The elevated LAPTM4B-35 expression was associated with cancer recurrence (P = 0.031). The 5-year median OS and PFS were significantly worse in the LAPTM4B-35 overexpressed group. Multivariate Cox analysis showed that LAPTM4B-35 over-expression was an independent factor for OS and PFS in NSCLC(P = 0.018, P = 0.026, respectively). The overexpressed LAPTM4B-35 was an independent prognostic biomarker for NSCLC, which could predict cancer recurrence and poor over survival. And that may be applied as potential target for NSCLC treatment.